Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women

被引:22
作者
Brinkoetter, Mary [1 ]
Magkos, Faidon [1 ]
Vamvini, Maria [1 ]
Mantzoros, Christos S. [1 ,2 ,3 ]
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA
[2] Boston Vet Affairs Healthcare Syst, Endocrinol Sect, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM | 2011年 / 301卷 / 01期
基金
美国国家卫生研究院;
关键词
muscle mass; fat-free mass; reproductive dysfunction; RECOMBINANT HUMAN LEPTIN; MUSCLE MASS; HYPOTHALAMIC AMENORRHEA; INSULIN-RESISTANCE; HEALTHY-MEN; WEIGHT-LOSS; GENE; MICE; EXPRESSION; NEUROENDOCRINE;
D O I
10.1152/ajpendo.00146.2011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Brinkoetter M, Magkos F, Vamvini M, Mantzoros CS. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women. Am J Physiol Endocrinol Metab 301: E99-E104, 2011. First published April 19, 2011; doi: 10.1152/ajpendo.00146.2011.-Animal studies in vivo indicate that leptin treatment in extremely leptin-sensitive ob/ob mice reduces body weight exclusively by reducing fat mass and that it increases muscle mass by downregulating myostatin expression. Data from human trials are limited. Therefore, we aimed at characterizing the effects of leptin administration on fat mass, lean body mass, and circulating regulators of muscle growth in hypoleptinemic and presumably leptin-sensitive human subjects. In an open-label, single-arm trial, seven lean, strenuously exercising, amenorrheic women with low leptin concentrations (<= 5 ng/ml) were given recombinant methionyl human leptin (metreleptin; 0.08 mg.kg(-1).day(-1)) for 10 wk. In a separate randomized, double-blind, placebo-controlled trial, seven women were given metreleptin (initial dose: 0.08 mg.kg(-1).day(-1) for 3 mo, increased thereafter to 0.12 mg.kg(-1).day(-1) if menstruation did not occur), and six were given placebo for 9 mo. Metreleptin significantly reduced total body fat by an average of 18.6% after 10 wk (P < 0.001) in the single-arm trial and by 19.5% after 9 mo (placebo subtracted; P for interaction = 0.025, P for metreleptin = 0.004) in the placebo-controlled trial. There were no significant changes in lean body mass (P >= 0.33) or in serum concentrations of myostatin (P >= 0.35), follistatin (P >= 0.30), and activin A (P >= 0.20) whether in the 10-wk trial or the 9-mo trial. We conclude that metreleptin administration in lean hypoleptinemic women reduces fat mass exclusively and does not affect lean body mass or the myostatin-follistatin-activin axis.
引用
收藏
页码:E99 / E104
页数:6
相关论文
共 34 条
[1]  
BALLOR DL, 1994, INT J OBESITY, V18, P35
[2]  
BALLOR DL, 1991, INT J OBESITY, V15, P717
[3]   Differential regulation of metabolic, neuroendocrine, and immune function by leptin in humans [J].
Chan, Jean L. ;
Matarese, Giuseppe ;
Shetty, Greeshma K. ;
Raciti, Patricia ;
Kelesidis, Iosif ;
Aufiero, Daniela ;
De Rosa, Veronica ;
Perna, Francesco ;
Fontana, Silvia ;
Mantzoros, Christos S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (22) :8481-8486
[4]   Transcriptional pathways associated with skeletal muscle disuse atrophy in humans [J].
Chen, Yi-Wen ;
Gregory, Chris M. ;
Scarborough, Mark T. ;
Shi, Rongye ;
Walter, Glenn A. ;
Vandenborne, Krista .
PHYSIOLOGICAL GENOMICS, 2007, 31 (03) :510-520
[5]   Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice [J].
Choi, Sun Ju ;
Yablonka-Reuveni, Zipora ;
Kaiyala, Karl J. ;
Ogimoto, Kayoko ;
Schwartz, Michael W. ;
Wisse, Brent E. .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2011, 300 (06) :E1031-E1037
[6]   Leptin is an effective treatment for hypothalamic amenorrhea [J].
Chou, Sharon H. ;
Chamberland, John P. ;
Liu, Xiaowen ;
Matarese, Giuseppe ;
Gao, Chuanyun ;
Stefanakis, Rianna ;
Brinkoetter, Mary T. ;
Gong, Huizhi ;
Arampatzi, Kalliopi ;
Mantzoros, Christos S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (16) :6585-6590
[7]   Leptin in human physiology and therapeutics [J].
Dardeno, Tina A. ;
Chou, Sharon H. ;
Moon, Hyun-Seuk ;
Chamberland, John P. ;
Fiorenza, Christina G. ;
Mantzoros, Christos S. .
FRONTIERS IN NEUROENDOCRINOLOGY, 2010, 31 (03) :377-393
[8]   Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency [J].
Farooqi, IS ;
Matarese, G ;
Lord, GM ;
Keogh, JM ;
Lawrence, E ;
Agwu, C ;
Sanna, V ;
Jebb, SA ;
Perna, F ;
Fontana, S ;
Lechler, RI ;
DePaoli, AM ;
O'Rahilly, S .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (08) :1093-1103
[9]   Leptin and the regulation of body weight in mammals [J].
Friedman, JM ;
Halaas, JL .
NATURE, 1998, 395 (6704) :763-770
[10]   Congenital leptin deficiency due to homozygosity for the Δ133G mutation:: Report of another case and evaluation of response to four years of leptin therapy [J].
Gibson, WT ;
Farooqi, IS ;
Moreau, M ;
DePaoli, AM ;
Lawrence, E ;
O'Rahilly, S ;
Trussell, RA .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (10) :4821-4826